213 results about "Enteritides" patented technology

The invention discloses an enteritis patient condition severity risk early warning method, a medium and equipment. The method comprises the following steps: acquiring a borborygmus original signal and a clinical multi-dimensional physiological parameter sequence through a sensing device; constructing a borborygmus dynamic characteristic spectrum based on the borborygmus original signal to generate an acoustic biomarker time sequence; inputting the acoustic biomarker time sequence and the clinical multi-dimensional physiological parameter sequence into a multi-modal fusion early warning model to obtain an intestinal inflammation risk index; executing a signal quality self-evaluation process and generating a data quality warning code when the signal quality is abnormal; triggering a multi-node collaborative monitoring mechanism based on the risk index to generate an intestinal state multi-dimensional situation map; establishing an individualized risk baseline and generating a graded early warning instruction; and finally outputting a comprehensive early warning report. According to the method, multi-modal fusion analysis of the borborygmus signal and the clinical parameters is realized, the accuracy and timeliness of illness state early warning are remarkably improved through dynamic risk assessment and signal quality monitoring, and a reliable basis is provided for clinical decision making.

The present invention belongs to the field of biotechnology and relates to a five - plex fluorescence PCR detection reagent for Salmonella, Salmonella enteritidis, Salmonella typhimurium, Salmonella pullorum and Salmonella gallinarum and its application. By using the five - plex fluorescence PCR detection reagent of the present invention, the purpose of simultaneously identifying and detecting Salmonella enteritidis, Salmonella typhimurium, Salmonella pullorum and Salmonella gallinarum can be achieved. It has the advantages of simple operation, rapidity, high accuracy, high sensitivity and good repeatability, and is of great significance for the rapid and accurate detection of clinical animal salmonellosis and epidemic disease prevention and control.

The invention belongs to the technical field of microbiological detection, and discloses a composite probe for detecting salmonella enteritidis and a preparation method. The composite probe for detecting the salmonella enteritidis comprises magnetic nanoparticles FeO, wherein the surface of the magnetic nanoparticles FeO is modified with an aptamer apt which is specifically combined with the salmonella enteritidis; the surface of the long afterglow nano particle PLNPs is modified with a DNA (Deoxyribose Nucleic Acid) sequence cDNA (Complementary Deoxyribonucleic Acid) complementary with the aptamer; the aptamer apt and the complementary DNA sequence cDNA are subjected to hybridization to form a composite probe structure FeO-SEapt (at) PLNPs-cDNA (complementary deoxyribonucleic acid). The long afterglow luminescence characteristic of PLNPs (ZnGaO: Cr) is utilized, and an excitation light source is stopped before detection, so that signal acquisition completely avoids autofluorescence of a sample matrix, background fluorescence interference is thoroughly eliminated, and the signal-to-noise ratio is remarkably improved.

The invention belongs to the technical field of food microorganism detection, and provides a lateral flow chromatography kit for high-sensitivity quantitative detection of salmonella enteritidis, which comprises a salmonella enteritidis RPA primer group and a lateral flow chromatography test strip, raman label streptavidin, a Digoxin antibody and a streptavidin antibody are coated on the lateral flow chromatography test strip. The reporter probe is combined on the release pad of the flow measurement chromatography test strip, has two characteristics of colorimetry and SERS (Surface Enhanced Raman Scattering), can finish simultaneous qualitative and quantitative detection of pathogenic bacteria, and improves the detection sensitivity; and the Digoxin antibody and the streptavidin antibody are respectively combined on the detection line and the quality control line. The kit does not need to use large experimental equipment in the whole detection process, is high in detection accuracy and good in specificity, and is very suitable for real-time detection under the condition of relatively low development level.

The invention provides a strain of high-temperature-resistant and inflammation-relieving Witzia ciliaris and an application thereof, the high-temperature-resistant and inflammation-relieving Witzia ciliaris is Witzia ciliaris CN985 and is preserved in the China Center for Type Culture Collection (CCTCC), the preservation date is April 7, 2024, and the preservation number is CCTCC NO: M 2024641. The invention further provides a preparation method of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain for preventing and treating inflammation of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain for preventing and treating inflammation of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain. The invention provides a brand new strain of Witzia ciliaris CN985, which is resistant to high temperature, has better acid resistance and bile resistance, and has no hemolysis risk when being applied to a human body. The Witzia coagulans CN985 has excellent antibacterial performance, and especially can significantly inhibit streptococcus pyogenes, salmonella enteritidis and / or group B streptococcus; besides, experimental results show that the Witzia ciliaris CN985 can relieve enteritis, improve the immunity of the organism and relieve pharyngitis, and especially when the Witzia ciliaris CN985 and the phytobacterium plantarum CE18 are combined for use, the Witzia ciliaris CN985 and the phytobacterium plantarum CE18 have a synergistic interaction effect, so that the relieving effect on enteritis can be remarkably improved.

The invention relates to the technical field of microorganisms, and particularly discloses a metagen as well as a preparation method and anti-inflammatory application thereof. The method for preparing the metagen comprises the following steps: (1) carrying out solid-state fermentation by taking bacillus amyloliquefaciens CAU X1 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.26769 and bacillus coagulans B2 with the preservation number of CGMCC No.26767 as zymophyte together, so as to obtain a fermentation product, wherein the bacillus amyloliquefaciens CAU X1 and the bacillus coagulans B2 are used as zymophyte together, and the bacillus amyloliquefaciens CAU X1 and the bacillus coagulans B2 are used as zymophyte together; (2) extracting the fermentation product by using a water-soluble solvent, centrifuging to take supernatant, and freeze-drying to obtain powder; or extracting the fermentation product by using an organic solvent, centrifuging and taking the supernatant, and volatilizing the organic solvent to obtain the extract. The metagen provided by the invention has anti-inflammatory activity, can improve bacterial enteritis, can play roles in resisting inflammation, regulating body immunity, optimizing intestinal flora structure and improving bacterial enteritis, can be used for medicines or feed additives, and has a good application prospect.

Bacillus strains useful for preventing and / or controlling Clostridium perfringens infections and necrotic enteritis in monogastric animals, such as swine and poultry, and for improving the overall health, feed conversion rates and body weight gain of such animals, as well as compositions comprising the Bacillus strains and various methods of using the Bacillus strains in animal feed and animal feed additives.

The invention relates to the technical field of microorganisms, in particular to a lactobacillus plantarum strain LM2 and application of the lactobacillus plantarum strain LM2. The strain has relatively high GABA (gamma-aminobutyric acid) production capacity and nitrite degradation capacity, has a bacteriostatic effect on intestinal pathogens such as staphylococcus aureus, salmonella enteritidis, listeria monocytogenes and campylobacter jejuni, has a good bacteriostatic function, also has good acid resistance and cholate resistance, and can be used for preparing a bacterial strain for treating intestinal diseases. The strain can well survive in artificial intestinal juice and artificial gastric juice; in order to increase the yield of GABA, the accelerant capable of remarkably promoting the growth of the strain LM2 is obtained by researching the accelerant, and the highest survival rate of the freeze-dried powder prepared by optimizing the accelerant and the freeze-dried powder can reach 99% or above, the nitrite degradation rate can reach 99% or above, the yield of GABA is increased to 3.0 g / L or above, and the freeze-dried powder is bacterial powder capable of being widely applied.

The present invention provides a strain of the genus Alistipes as well as a pharmaceutical composition comprising the strain or an extract of the strain. The strain and the pharmaceutical composition disclosed by the invention can be used for remarkably relieving such symptoms as weight loss, shortened colon length, inflammatory factor release and the like of an enteritis object, and do not have toxic or side effects. Therefore, the another mycobacterium strain or the active extract of the another mycobacterium strain can be used for preparing pharmaceutical compositions and fermented foods for relieving enteritis, and has a very wide application prospect.

The invention provides a decapterus maruadsi deepwater net cage culture method, and belongs to the technical field of decapterus maruadsi culture. According to the method, the submersible net cage is adopted, the decapterus maruadsi is located in the optimal growth water layer at the temperature of 20-25 DEG C all the year round according to rising and falling of seasons (surface water temperature), a guide pipe is adopted for fixed-point feed feeding, and the feed coefficient is reduced to 1.25 or below. According to the method, a water temperature-feeding amount-allicin-probiotics coupling model is established, the enteritis incidence rate in the high-temperature period is controlled within 2%, and annual continuous growth of decapterus maruadsi in deep and far sea is achieved.

The invention relates to a novel polypeptide and application thereof. The polypeptide provided by the invention is short in peptide chain and faster and better in absorption. Experimental results show that the polypeptide provided by the invention shows an obvious enteric cavity dilatation relieving effect in pharmacodynamic tests of a zebra fish inflammatory bowel disease model and a rat inflammatory bowel disease model. The polypeptide provided by the invention has a remarkable colitis relieving effect, and can be used for preparing a medicine for treating enteritis, especially a medicine for treating ulcerative colitis.

This invention belongs to the field of molecular biology detection technology, specifically relating to a primer and probe combination for detecting avian Salmonella based on the RAA-LFD method and its application, particularly to a primer and probe combination for detecting three avian serotypes of Salmonella: Salmonella pullorum, Salmonella enteritidis, and Salmonella typhimurium, based on the RAA-LFD method and its application. This invention designs different types of probes and primers targeting the genes of serotypes SP, SE, and STM of Salmonella. Using the primer and probe combination of this invention, rapid, sensitive, and specific detection of Salmonella serotypes and the three avian Salmonella serotypes SP, SE, and STM can be achieved, greatly shortening the detection cycle of avian salmonellosis and improving the detection efficiency and accuracy of avian salmonellosis.

A novel bacteriophage having bacteriolytic activity against bacteria of the genus Salmonella, such as S. Enteritidis, and a bacteriolytic agent consisting of the same are provided. The bacteriophage and the bacteriolytic agent including the bacteriophage have a wide host range for bacteria of the genus Salmonella. A host-specific bacteriophage and an effective Salmonella bacteriolytic agent consisting of the same are provided. A bacteriophage capable of effectively controlling S. Typhimurium, and in particular, multidrug-resistant S. Typhimurium, and a bacteriolytic agent consisting of the same are also provided. A bacteriophage having a specific genomic DNA sequence; a Salmonella bacteriolytic agent consisting of the bacteriophage; and a composition comprising the same are provided.

The present invention relates to a new polypeptide and its application. The polypeptide provided by the present invention has a short peptide chain and is absorbed faster and better. Experimental results show that the polypeptide provided in this application exhibits an obvious effect of alleviating intestinal lumen dilation in the zebrafish inflammatory bowel disease model and the rat inflammatory bowel disease model. The polypeptide provided by the present invention has a significant effect of alleviating colitis and can be used to prepare drugs for treating enteritis, especially drugs for ulcerative colitis.

The invention discloses a multifunctional probiotic engineering bacterium capable of continuously producing melanin in situ in vivo and application of the multifunctional probiotic engineering bacterium. According to the application, a genetically engineered bacterium EcN-Mel is constructed by adopting a probiotic Escherichia coli 1917 (EcN), and the EcN-Mel has the advantages of oral safety, continuous in-situ melanin production, inflammation site targeting and multi-mechanism synergistic treatment of acute radiation enteritis; researches find that EcN-Mel has a better curative effect on acute radiation enteritis than EcN; compared with the traditional Chinese medicine composition, the traditional Chinese medicine composition has stronger free radical scavenging capability, stronger capability of reducing inflammation level, stronger capability of increasing intestinal beneficial flora and reducing harmful flora, stronger capability of targeting a focus part-intestinal inflammation part, higher survival rate in a stomach acidic environment, longer retention time in the intestinal inflammation part, concentration increased by about 3 times, and more stable in vivo.

The microorganism strain Pediococcus acidilactici TAK 589 CoccobEst is a new antimicrobial and antioxidant probiotic, CoccobEst inhibits the growth of the enteropathogens L. monocytogenes, E. coli, S. enteritidis, S. typhimurium, S. sonnei, S. aureus, E. faecalis and C. sakazakii, but does not inhibit lactobacilli of natural intestinal microbiota. The strain's antimicrobial properties are enhanced by periplasmic peptidoglycan hydrolases with proteolytic activity. CoccobEst is used as a zootechnieai feed additive to prevent bacterial infections in the gastrointestinal tract of farm animals and pets and to prevent and reduce diarrhea. CoccobEst has highly active antioxidant defense system, increasing the redox activity of glutathione and reducing oxidative stress in cells. Therefore, CoccobEst is used as a food supplement or functional food for humans to prevent bacterial infections of the gastrointestinal tract and to prevent and reduce oxidative stress. In addition, CoccobEst is used as a starter culture in fermentation of vegetables.

The present disclosure provides a method of reducing, preventing or treating an intestinal infection, preventing or treating a disease associated with protozoan parasite of the genus Eimeria, inhibiting an oocyst sporulation of a protozoan parasite or preventing a sporozoite invasion or reproduction, preventing or treating coccidiosis, promoting growth performance, controlling, treating and / or preventing necrotic enteritis in a subject, comprising administering to the subject an effective amount of a composition comprising a Crassocephalum rabens (CR), a bioactive extract thereof (CRE), an active ingredient(s) contained in a CR (CR_API) or CRE (CRE_API), a combination of two or more of a CR, a CRE, a CR_API and a CRE_API, or one or more of a-linolenic acid, citric acid, lactic acid, mannitol, palmitic acid, aspartic acid and 1-monomyristin.

The application discloses application of T1FR protein in inhibition of Klebsiella pneumoniae and Salmonella enteritidis type I fimbriae, and relates to the field of biotechnology. T1fr The biological factor T1FR protein encoded by the gene can inhibit Klebsiella pneumoniae and Salmonella enteritidis type I fimbriae adhesion factors, and can effectively reduce the use of antibiotics and relieve the drug resistance of Klebsiella pneumoniae and Salmonella by inhibiting pathogenic bacteria adsorption and colonization in human and animal tissues, thereby providing a theoretical basis and an important reference scheme for controlling bacterial infection and biofilm formation.

The present invention relates to immunogenic compositions comprising antigens derived from Salmonella enterica serotype tiphimurium (S. Typhimurium), Salmonella enterica serotype enteritidis (S. Enteritidis), and Salmonella enterica serotype typhi (S. Typhi). The present invention further relates to methods and compositions comprising GMMA for boosting the immune response to the S. Typhi antigen, vaccines and methods comprising immunogenic compositions, and the use of immunogenic compositions.

The application discloses a bocachito Nat10 antibacterial peptide, a coding sequence and use and a preparation method thereof, and relates to a method based on multiomics, a biological big data based on multiomics data of bocachito, screening and identifying an antibacterial peptide precursor gene sequence, and obtaining an amino acid sequence of the bocachito Nat10 antibacterial peptide through translation design, as shown in SEQ ID NO: 3. Through activity simulation prediction and in-vitro experiment verification, the bocachito Nat10 antibacterial peptide shows inhibitory effects on the growth activities of Streptococcus agalactiae, Salmonella enteritidis, Staphylococcus aureus, Vibrio anguillarum and Escherichia coli, especially on Staphylococcus aureus, and shows the best antibacterial effect at a concentration of 2.5 micromoles per liter. The bocachito Nat10 antibacterial peptide can be used for preparing various bactericidal preparations, including bacteriostatic agents, medicines or additives, and has good practical value and social ecological benefits.

The present invention relates to a strain of Lactobacillus johnsonii N5 and its application in preventing and treating enteritis and diarrhea. Lactobacillus johnsonii N5), was deposited in the China Center for Type Culture Collection on February 10, 2023, with the deposit number CCTCC NO: M2023104. The Lactobacillus johnsonii N5 was isolated from the fecal microorganisms of piglets resistant to heat stress-induced diarrhea. This Lactobacillus johnsonii N5 has the effect of alleviating enteritis and diarrhea, which is specifically reflected in: significantly enhancing the expression of intestinal epithelial tight junction proteins and cytoprotective heat shock protein 70, improving the immune balance of animal intestinal T cells, enhancing immune tolerance, and reducing the degree of intestinal inflammation and the occurrence of diarrheal diseases in animals. Therefore, Lactobacillus johnsonii N5 has a significant effect in preventing and treating diarrhea and related intestinal inflammatory diseases.

The invention provides an application of N4BP1 in preparation of an anti-enteritis drug, relates to the technical field of biomedicine, and particularly provides an application of N4BP1 as an inhibition target in preparation of an anti-enteritis drug. Researches show that the deletion of N4BP1 can alleviate colon pathological changes and weight loss caused by DSS, increase the survival days of mice, and reduce the generation of inflammatory factors and chemotactic factors. In addition, DSS can cause increase of N4BP1 expression in mice. Therefore, occurrence and development of enteritis can be inhibited by knocking out the N4BP1, the N4BP1 inhibitor or the N4BP1 neutralizing antibody, namely, the N4BP1 can become a new target spot for treating enteritis. Meanwhile, the expression of the N4BP1 can also be used as a new index for enteritis detection.

The invention belongs to the technical field of disease control in aquaculture, and particularly relates to a hippocampus enteritis pathogen separation and identification and medication screening method based on a high-throughput sequencing technology, which comprises the following steps: collecting intestinal tissues of a diseased hippocampus and a healthy hippocampus, respectively preparing tissue homogenate, and freezing for preservation; the method comprises the following steps: extracting DNA (Deoxyribose Nucleic Acid) of microorganisms of an intestinal tissue sample, performing 16SrDNA high-throughput sequencing, analyzing intestinal flora composition, and determining dominant bacteria; selecting and screening a culture medium according to dominant bacteria, and performing pathogenic bacterium separation and purification on intestinal tissues of the diseased hippocampus; dNA of the purified strain is extracted, 16S rDNA amplification and sequencing are carried out, and the species of pathogenic bacteria are identified through sequence comparison; according to the method, the diversity and abundance differences of microorganisms in the sick hippocampus and the healthy hippocampus are compared through a high-throughput sequencing technology, and targeted separation, identification and drug sensitivity screening are further carried out by taking statistically significant difference bacteria as the guidance of potential pathogenic bacteria.

The application discloses a gene prdR for regulating myxobacteria predation and a protein coded by the gene, and belongs to the technical field of biotechnology. The mutant DK10 with significantly improved predation capacity is obtained by using the strategy of adaptive evolution; genetic variation sites of the mutant DK10 are analyzed by using the bacterial genome resequencing technology, and functions of the genetic variation sites are researched by using the gene knockout technology, and it is found that the gene deletion of MXAN_2902 (prdR, the nucleotide sequence is shown as SEQ ID NO. 1) significantly enhances the predation capacity of Myxococcus xanthus. The nucleic acid sequence and the amino acid sequence of the transcriptional activator PrdR for regulating the predation of Myxococcus xanthus are disclosed, and the functional strain of Myxococcus xanthus capable of efficiently predating Salmonella enteritidis can be developed by using the prdR gene, and a new strategy is provided for the prevention and control of drug-resistant HVPG pathogenic bacteria.

The application discloses application of a natural oyster zinc peptide product in preparation of a medicine for preventing and treating enteritis. The application verifies the function of the natural oyster zinc peptide product in preventing and treating enteritis through animal experiments, the natural oyster zinc peptide product can improve the apparent symptoms of ulcerative colitis of mice caused by DSS by regulating the oxidation stress level, relieving the inflammatory reaction, maintaining the intestinal barrier and reducing the cell apoptosis, and the natural oyster zinc peptide product can also regulate the intestinal flora and metabolic products of the intestinal flora of the enteritis mice, so that the intestinal inflammation is relieved. The natural oyster zinc peptide product used in the application has good safety, compared with common anti-inflammatory and immunity-enhancing medicines, the natural oyster zinc peptide product has lower cost and no side effect, and the effect of relieving enteritis is remarkable. Therefore, the natural oyster zinc peptide product has a good prospect in development of medicines for preventing and treating enteritis.

The invention discloses a traditional Chinese medicine composition, a decoction, granules and application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 5-15 parts of radix scutellariae, 3-7 parts of rhizoma coptidis, 5-15 parts of radix puerariae, 5-15 parts of radix paeoniae alba, 8-16 parts of radix angelicae sinensis, 5-15 parts of raw radix sanguisorbae, 10-20 parts of herba portulacae, 4-8 parts of radix aucklandiae and 3-7 parts of honey-fried licorice root. The traditional Chinese medicine composition not only can directly act on the cause of damp-heat, but also can comprehensively cover enteritis symptoms such as abdominal pain, diarrhea, tenesmus, bloody purulent stool and the like, can relieve the disadvantage that the stomach is injured by bitter and cold medicines, is strong in clinical pertinence, and is suitable for enteritis caused by ulcerative colitis, bacteria, viruses, radioactivity and the like; the traditional Chinese medicine composition can also be matched with probiotics to treat western medicine chronic diarrhea and traditional Chinese medicine diarrhea. Therefore, the traditional Chinese medicine composition or the decoction and the granules thereof have the prospect of being developed into the medicine for treating enteritis or the prospect of being developed into the medicine for treating western medicine chronic diarrhea and traditional Chinese medicine diarrhea in cooperation with the probiotics.

The invention relates to a novel polypeptide and application thereof. The polypeptide provided by the invention is short in peptide chain and faster and better in absorption. Experimental results show that the polypeptide provided by the invention shows an obvious enteric cavity dilatation relieving effect in pharmacodynamic tests of a zebra fish inflammatory bowel disease model and a rat inflammatory bowel disease model. The polypeptide provided by the invention has a remarkable colitis relieving effect, and can be used for preparing a medicine for treating enteritis, especially a medicine for treating ulcerative colitis.

The invention relates to the technical field of microorganisms, in particular to a lactobacillus plantarum strain LS2 and application thereof.The lactobacillus plantarum strain LS2 is separated from cheese, has the high GABA production capacity and the nitrite degradation capacity, has the antibacterial effect on enteric pathogenic bacteria including escherichia coli, salmonella enteritidis and campylobacter jejuni, and has the advantages that the lactobacillus plantarum strain LS2 is high in GABA production capacity and nitrite degradation capacity; the strain has good antibacterial function, good acid resistance and cholate resistance, and can well survive in artificial intestinal juice and artificial gastric juice; in order to improve the yield of GABA, the accelerant capable of remarkably promoting the growth of the strain LS2 is obtained by researching the accelerant, the highest survival rate of the freeze-dried powder prepared by optimizing the accelerant and the freeze-dried powder can reach 99% or above, the nitrite degradation rate can reach 98% or above, the yield of GABA is improved to 3.3 g / L or above, and the freeze-dried powder is bacterial powder capable of being widely applied.

The application provides an EcNc engineering bacterium constitutively expressing MLH protein and application in treating intestinal inflammation, and belongs to the technical field of biological medicine. The application provides an EcNc engineering bacterium constitutively expressing MLH protein, taking Escherichia coli Nissle 1917 (EcN) as a chassis cell, and then introducing the reconstructed endogenous cryptic plasmid pMUT1 and / or pMUT2 after removing two hidden plasmids; the reconstruction is that a fusion protein MLH coding gene formed by using a flexible linker to connect SOD and CAT is inserted into pMUT1 and / or pMUT2. The application constructs an engineering bacterium constitutively expressing a fusion protein, and the engineering bacterium can express the fusion protein with double enzyme activities of SOD and CAT without antibiotic pressure and IPTG induction. The engineering bacterium constructed by the application can be used as an engineered microorganism for treating UC disease, for example, as a live bacterial drug.